Login / Signup

Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).

Kristy Kummerow BromanTasha HughesLesly DossettJames SunDennis KirichenkoMichael J CarrAvinash SharmaMadalyn G NeuwirthAmanda A G NijhuisJohn F ThompsonTina J HiekenLisa KottschadeJennifer DownsDavid E GyorkiEmma StahlieAlexander van AkkooiDavid W OllilaJill FrankYun SongGiorgos C KarakousisMarc MoncrieffJenny NobesJohn VettoDale HanJeffrey M FarmaJeremiah L DeneveMartin D FlemingMatthew C PerezMichael C LoweRoger Olofsson BaggeJan MattssonAnn Y LeeRussell S BermanHarvey ChaiHidde M KroonJuri TerasRoland M TerasNorma E FarrowGeorgia BeasleyJane Yuet Ching HuiLukas BeenSchelto KruijffYoungchul KimSyeda Mahrukh Hussnain NaqviAmod A SarnaikVernon K SondakJonathan S Zager
Published in: Cancer (2021)
For patients with melanoma of the skin and microscopic spread to lymph nodes, monitoring with ultrasound is an alternative to surgically removing the remaining lymph nodes. The authors studied adoption and real-world outcomes of ultrasound monitoring in over 1000 patients treated at 21 centers worldwide, finding that most patients now have ultrasounds instead of surgery. Although slightly more patients have cancer return in the lymph nodes with this strategy, typically, it can be removed with delayed surgery. Compared with up-front surgery, ultrasound monitoring results in the same overall risk of melanoma coming back at any location or of dying from melanoma.
Keyphrases